Short answer
THC has more human data for PTSD than CBDA. A 2015 trial of nabilone, a synthetic THC analog, tested 10 Canadian Forces members with PTSD-related nightmares. Nightmare frequency and intensity fell versus placebo. CBDA has no published human PTSD trial. The FDA has approved no cannabis product for PTSD.
What each compound is
CBDA is cannabidiolic acid, the acid form of CBD in raw cannabis. Heat converts CBDA to CBD. Lab tests show CBDA acts at the 5-HT1A receptor. It does not cause intoxication.
best cannabis strains for ptsd nightmares
THC is delta-9-tetrahydrocannabinol. It binds CB1 and CB2 receptors. CB1 activation produces intoxication, short-term memory impairment, and a rise in heart rate. Tolerance and dependence occur in a share of long-term users.
THC and PTSD: the human data
THC research for PTSD is small. The nabilone crossover trial (Jetly et al., 2015) enrolled 10 men and ran 7 weeks per arm. Two later chart reviews and one open-label study reported symptom changes. Sample sizes ranged from 10 to about 100. No phase 3 trial exists, and no THC product carries a PTSD indication.
Veterans Using Cannabis for PTSD: A Comprehensive Guide
Side effects in those studies: sedation, dizziness, dry mouth. Nabilone is a prescription drug in the U.S. for chemotherapy-induced nausea, not PTSD.
CBDA and PTSD: the human data
None. PubMed lists no human trial of CBDA for PTSD as of 2025. CBDA work sits in animal models and lab assays. Rat studies report anti-nausea and anti-anxiety effects. Human doses and bioavailability are unmeasured in controlled settings. CBDA is unstable and converts to CBD with heat, light, or time.
Side by side
- Human PTSD trials: THC, several small ones. CBDA, zero.
- Intoxication: THC, yes. CBDA, no.
- Receptor target: THC, CB1 and CB2. CBDA, 5-HT1A in lab work.
- FDA status for PTSD: neither.
- Prescription form: nabilone, a THC analog. None for CBDA.
- Evidence quality: both low. THC has more of it.
Which to pick
For research reading, start with the THC and nabilone papers. That is where human PTSD data exists. For a product with no intoxication, CBDA or CBD fits, but the PTSD evidence is thin. Neither choice replaces trauma-focused therapy or prescribed medication.
Options in a legal market
High-CBD, low-THC tincture
The label shows CBD and THC percentages plus total mg per bottle. Common ratios run 10:1 to 20:1 CBD to THC. Lab reports list pesticides and residual solvents.
CBDA raw product
Sold as raw flower, juice, or raw oil. THC content stays under 0.3% in hemp-derived versions. Shelf life is short. Potency tests vary by batch.
THC-dominant flower or edible
Dose is measured in mg THC per serving. State limits cap edible servings at 10 mg in most legal markets. Keep the package and a dose log.
Nabilone, prescription only
Not sold at dispensaries. A physician writes it. Approved for nausea, used off-label in some PTSD cases.
Legal and safety notes
Cannabis law varies by state. PTSD is a qualifying condition for medical cannabis in several states, not all. Driving after THC use is illegal in every state. Heavy THC use carries risk of cannabis use disorder. Tell your prescriber about all cannabis use.